These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo. Kollárová-Brázdová P; Lenčová-Popelová O; Karabanovich G; Kocúrová-Lengvarská J; Kubeš J; Váňová N; Mazurová Y; Adamcová M; Jirkovská A; Holečková M; Šimůnek T; Štěrbová-Kovaříková P; Roh J; Štěrba M Clin Sci (Lond); 2021 Aug; 135(15):1897-1914. PubMed ID: 34318878 [TBL] [Abstract][Full Text] [Related]
5. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors. Ding S; Xiong S; Wang X; Zhang C; Chen S; Sun M; Wu C; Zhang X; Wang M; Wang J; Shang X Clin Transl Oncol; 2024 Jun; 26(6):1459-1466. PubMed ID: 38329609 [TBL] [Abstract][Full Text] [Related]
6. Plasmatic and chamber-specific modulation of cardiac microRNAs in an acute model of DOX-induced cardiotoxicity. Gioffré S; Ricci V; Vavassori C; Ruggeri C; Chiesa M; Alfieri I; Zorzan S; Buzzetti M; Milano G; Scopece A; Castiglioni L; Sironi L; Pompilio G; Colombo GI; D'Alessandra Y Biomed Pharmacother; 2019 Feb; 110():1-8. PubMed ID: 30453253 [TBL] [Abstract][Full Text] [Related]
7. Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice. Stark C; Taimen P; Savunen T; Koskenvuo J BMC Res Notes; 2018 Feb; 11(1):148. PubMed ID: 29467032 [TBL] [Abstract][Full Text] [Related]
8. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314 [TBL] [Abstract][Full Text] [Related]
9. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model. Razmaraii N; Babaei H; Mohajjel Nayebi A; Asadnasab G; Ashrafi Helan J; Azarmi Y J Cardiovasc Pharmacol; 2016 Mar; 67(3):237-45. PubMed ID: 26544684 [TBL] [Abstract][Full Text] [Related]
10. Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats. Liu G; Liu Y; Wang R; Hou T; Chen C; Zheng S; Dong Z Cardiovasc Ther; 2016 Aug; 34(4):216-24. PubMed ID: 27097055 [TBL] [Abstract][Full Text] [Related]
11. Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation. Bai Y; Chen Q; Sun YP; Wang X; Lv L; Zhang LP; Liu JS; Zhao S; Wang XL Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28636290 [TBL] [Abstract][Full Text] [Related]
12. Time course of cardiomyopathy induced by doxorubicin in rats. Medeiros-Lima DJM; Carvalho JJ; Tibirica E; Borges JP; Matsuura C Pharmacol Rep; 2019 Aug; 71(4):583-590. PubMed ID: 31174019 [TBL] [Abstract][Full Text] [Related]
14. Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. Milano G; Biemmi V; Lazzarini E; Balbi C; Ciullo A; Bolis S; Ameri P; Di Silvestre D; Mauri P; Barile L; Vassalli G Cardiovasc Res; 2020 Feb; 116(2):383-392. PubMed ID: 31098627 [TBL] [Abstract][Full Text] [Related]
15. The Bach1/HO-1 pathway regulates oxidative stress and contributes to ferroptosis in doxorubicin-induced cardiomyopathy in H9c2 cells and mice. Wang Y; Qiu J; Yan H; Zhang N; Gao S; Xu N; Wang C; Lou H Arch Toxicol; 2024 Jun; 98(6):1781-1794. PubMed ID: 38573338 [TBL] [Abstract][Full Text] [Related]
16. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833 [TBL] [Abstract][Full Text] [Related]